Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20634274 | 0.90 | NLRP3 (0.45) | NLRP3 | |
| SCHEMBL22433572 | 0.89 | RECQL (0.41) | GSTO1NLRP3 | |
| SCHEMBL22433382 | 0.88 | SOAT1 (0.39) | — | |
| SCHEMBL20634279 | 0.87 | MEN1 (0.48) | — | |
| SCHEMBL24922841 | 0.87 | KAT6A (0.39) | GSTO1NLRP3 | |
| SCHEMBL20636155 | 0.86 | GSTO1 (0.39) | GSTO1NLRP3 | |
| SCHEMBL22433083 | 0.86 | GSTO1 (0.36) | GSTO1NLRP3 | |
| SCHEMBL24922553 | 0.86 | MAOB (0.41) | GSTO1NLRP3 | |
| SCHEMBL24922447 | 0.85 | RECQL (0.37) | GSTO1NLRP3 | |
| SCHEMBL20636160 | 0.85 | GSTO1 (0.39) | GSTO1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | DRD2 3619/4885HTR2A 1126/4885HTR2C 2036/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | DRD2 3542/4885HTR2A 1137/4885HTR2C 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.